Boston Scientific highlights positive results of heart devices

Boston Scientific (BSX) has reported favorable results in almost a dozen studies that tested the company's cardiac resynchronization therapy (CRT) defibrillators, platinum chromium stent platforms, and transcatheter aortic valve replacement.

Boston Scientific presented the data at the American College of Cardiology's Annual Scientific Session.

In a long-term study of patients with mild heart failure, there was a 41% relative reduction in the risk of death in those who received a Boston Scientific defibrillator with CRT compared with patients who received just a defibrillator. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs